BioSpace News Archive

The science team indicates it is the first naturally occurring case of a nonhuman primate model of the syndrome and could lead to potential treatments.

The U.S. Department of Justice said the two charitable organizations, Good Days and Patient Access Network Foundation, allowed seven pharmaceutical companies to funnel money through their organization to provide Medicare patients with assistance in paying for medications developed by those companies.

Michigan State University researchers Sophia Lunt and Richard Lunt, a married couple, work in different departments, but have found a common ground that could lead to cancer diagnostics and therapies.

Despite the success Gilead Sciences has seen with its JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.

Ziopharm said the collaboration with the vaunted cancer research center will use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors in T cells.

Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.

Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study

Allakos Inc., a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, announced upcoming presentations at the American College of Gastroenterology 2019 Annual Scientific Meeting.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s third quarter 2019 financial results will be released after market close on Monday, November 4, 2019.